Health Care Archives - Page 43 of 478

1 minute read

Eliem Therapeutics Shifts From Neurology With New Found Focus On Autoimmune Diseases With Tenet Medicines Deal

April 11, 12:42 PM

Eliem Therapeutics will acquire Tenet Medicines, focusing on advancing TNT119, an anti-CD19 antibody for autoimmune diseases. Strategic alternatives explored. $120 million private placement. Acquisition expected mid-2024.

ELYM

1 minute read

Why Is Cancer-Focused Janux Therapeutics Stock Trading Higher On Thursday?

By Vandana Singh

April 11, 12:13 PM

Janux Therapeutics may be up for sale amid interest from major pharmaceutical firms. With shares quadrupling this year and a successful equity offering, Janux is making waves in the industry. The pharmaceutical industry has seen a surge in deal activities, with acquisitions totaling $27.8 billion since the year's start.

JANX

2 minute read

Did UnitedHealth Execs Break Security Laws? Company Faces Scrutiny Over Executives’ Stock Sales Amid Antitrust Probe

By Vandana Singh

April 11, 12:08 PM

Reports reveal UnitedHealth executives profited $101.5 million from stock sales ahead of a DOJ antitrust inquiry announcement. Speculation surrounds the timing and approval of these trades amid ongoing investigations.

UNH

2 minute read

Declining COVID-19 Vaccine Sales Pinches Moderna, Pauses Kenya Vaccine Plant Plans

By Vandana Singh

April 11, 11:24 AM

Moderna pauses plans for Kenya vaccine plant amid declining COVID-19 vaccine demand in Africa. Losses from unfulfilled orders prompt strategic shift. Efforts to finalize deal with Kenyan government stalled despite incentives.

MRK

2 minute read

Rare Disease-Focused Rallybio Inks Development Pact With Johnson & Johnson, Stock Shoots Higher

By Vandana Singh

April 11, 9:27 AM

Rallybio partners with Johnson & Johnson to develop therapies targeting fetal and neonatal alloimmune thrombocytopenia, receiving $6.6 million investment. Phase 2 study for RLYB212 set for 2024.

JNJ

2 minute read

AstraZeneca Hikes Annual Dividend By 7% Just Before Vote On Its CEO’s Pay Package Boost

By Vandana Singh

April 11, 9:04 AM

AstraZeneca boosts its 2024 dividend to $3.10/share, reflecting confidence in performance. Shareholder concerns addressed as CEO compensation proposal approaches vote. Recent acquisitions and FDA approvals signal growth.

AZN

2 minute read

Vertex Pharmaceutical’s Move Beyond Its $10B Cystic Fibrosis Franchise, Pays Around $5B For Kidney Disease Player Alpine Immune

By Vandana Singh

April 11, 9:01 AM

Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion in cash. Povetacicept, a potent dual antagonist of BAFF and APRIL, shows promise in IgA nephropathy. Transaction expected to close Q2 2024. VRTX expanding into kidney disease treatment.

ALPN

2 minute read

Wall Street’s Most Accurate Analysts’ Views On 3 Health Care Stocks With Over 3% Dividend Yields

By Avi Kapoor

April 11, 7:48 AM

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

GSK

2 minute read

Amphastar Pharmaceuticals Interested In Potential Acquisitions In Endocrinology-Focused Companies

By Vandana Singh

April 10, 3:23 PM

Amphastar Pharmaceuticals discusses the future of Baqsimi at the Needham Healthcare Conference, highlighting its potential amid a growing market for glucagon products. With promising sales projections and strategic initiatives, Amphastar aims to capitalize on emerging opportunities in the endocrinology sector for continued growth.

AMPH

1 minute read

Blindness-Focused LENZ Therapeutics’ Investigational Eye Drop Ready To Revolutionize Presbyopia Landscape, Analyst Says

By Vandana Singh

April 10, 3:19 PM

Advances in presbyopia treatment with LENZ Therapeutics' LNZ100. Clinically proven to enhance near-vision for up to 10 hours, it offers a promising alternative to reading glasses. Analysts predict a bright future with a Buy rating and $34 price target.

ABBV